Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 26, 2026 01:15 ET | Source: Novartis Pharma AG

New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength

Late-breaking Phase III IgAN data for Vanrafia ALIGN and Fabhalta APPLAUSE-IgAN studies to be presented124-week Phase I/II zigakibart data evaluating treatment efficacy and safety in IgAN will be...
May 07, 2026 09:00 ET | Source: Novartis Pharma AG

Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities

US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent Hagenbuch, Novartis leadership mark expansion of company’s coast-to-coast RLT manufacturing network – the largest in the...
May 07, 2026 09:00 ET | Source: Novartis Pharma AG

Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities

US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent Hagenbuch, Novartis leadership mark expansion of company’s coast-to-coast RLT manufacturing network – the largest in the...
April 30, 2026 07:00 ET | Source: Novartis Pharma AG

Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility

At one-year mark, company has progressed all components of US investment plan to support delivery of innovative medicines to US patientsNew active pharmaceutical ingredients facility in North Carolina...
April 30, 2026 07:00 ET | Source: Novartis Pharma AG

Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility

At one-year mark, company has progressed all components of US investment plan to support delivery of innovative medicines to US patientsNew active pharmaceutical ingredients facility in North Carolina...
April 28, 2026 01:00 ET | Source: Novartis Pharma AG

Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed

Ad hoc announcement pursuant to Art. 53 LRFirst quarterNet sales declined -5% (cc1, -1% USD), as growth drivers were more than offset by US generic erosionContinued strong performance from priority...
April 28, 2026 01:00 ET | Source: Novartis Pharma AG

Novartis erzielte im ersten Quartal mit prioritären Marken und Neueinführungen ein starkes Wachstum; Prognose für das Geschäftsjahr 2026 bekräftigt

Ad-hoc-Mitteilung gemäss Art. 53 KR Erstes QuartalDer Nettoumsatz ging um –5% (kWk1, –1% USD) zurück, da Wachstumstreiber durch Einbussen durch Generika in den USA mehr als aufgehoben...
April 27, 2026 01:15 ET | Source: Novartis Pharma AG

Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria

Significant improvements as early as Week 1, favorable safety profile and no liver safety concerns in REMIX 1 & 2 studies of highly selective, oral BTKi1Rhapsido recommended in 2026...
April 24, 2026 06:30 ET | Source: Novartis Pharma AG

Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA)

If approved, Itvisma (intrathecal onasemnogene abeparvovec) will be first and only gene replacement therapy for children two years and older, teens and adults with SMA in the European UnionItvisma...
April 09, 2026 01:15 ET | Source: Novartis Pharma AG

Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030

Strengthens three community health models spanning community‑embedded care, earlier intervention and data‑driven population healthScales program footprint from 11 countries to more than 30 by 2030,...